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ABSTRACT
Objective To determine whether aspirin and antioxidant
therapy, combined or alone, are more effective than
placebo in reducing the development of cardiovascular
events in patients with diabetes mellitus and
asymptomatic peripheral arterial disease.
DesignMulticentre, randomised, double blind, 2×2
factorial, placebo controlled trial.
Setting16hospital centres in Scotland, supported by 188
primary care groups.
Participants 1276 adults aged 40 or more with type 1 or
type 2 diabetes and an ankle brachial pressure index of
0.99 or less but no symptomatic cardiovascular disease.
Interventions Daily, 100 mg aspirin tablet plus
antioxidant capsule (n=320), aspirin tablet plus placebo
capsule (n=318), placebo tablet plus antioxidant capsule
(n=320), or placebo tablet plus placebo capsule (n=318).
Main outcome measures Two hierarchical composite
primaryendpointsofdeath fromcoronaryheartdiseaseor
stroke, non-fatal myocardial infarction or stroke, or
amputation above the ankle for critical limb ischaemia;
and death from coronary heart disease or stroke.
ResultsNoevidencewas foundof any interactionbetween
aspirin and antioxidant. Overall, 116 of 638 primary
events occurred in the aspirin groups compared with 117
of 638 in the no aspirin groups (18.2% v 18.3%): hazard
ratio 0.98 (95% confidence interval 0.76 to 1.26). Forty
three deaths from coronary heart disease or stroke
occurred in the aspirin groups comparedwith 35 in the no
aspirin groups (6.7% v 5.5%): 1.23 (0.79 to 1.93). Among
the antioxidant groups117of 640 (18.3%)primary events
occurred compared with 116 of 636 (18.2%) in the no
antioxidant groups (1.03, 0.79 to 1.33). Forty two (6.6%)
deaths from coronary heart disease or stroke occurred in
the antioxidant groups comparedwith 36 (5.7%) in the no
antioxidant groups (1.21, 0.78 to 1.89).
Conclusion This trial does not provide evidence to support
the use of aspirin or antioxidants in primary prevention of
cardiovascular events andmortality in thepopulationwith
diabetes studied.
Trial registration Current Controlled Trials
ISRCTN53295293.
INTRODUCTION
Cardiovascular disease is themajor cause of morbidity
and mortality in patients with type 1 or type 2 diabetes
mellitus. These patients have been reported to have an
overall mortality of 50% within 40 years of diagnosis
comparedwith only 10% in a control population.1 This
increased mortality is mainly from ischaemic heart
disease23 and cerebrovascular disease, the incidence of
which is reported to be twofold to fivefold greater4 5
than the general population without diabetes.
Peripheral arterial disease is another powerful
indicator of systemic atheroma. Regardless of whether
symptoms are evident,6 patients with peripheral
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arterial disease have an increased risk of subsequent
myocardial infarction and stroke and are six times
more likely to die from cardiovascular disease within
10 years than patients without peripheral arterial
disease.7 Patientswithperipheral arterial diseasehave a
15 year accrued survival rate of about 22% compared
with a survival rate of 78% in patients without such
disease.8 9
The use of antiplatelet agents is known to reduce
future secondary cardiovascular events in patientswith
both diabetes mellitus and cardiovascular disease45
and inpatientswithperipheral arterial disease.410 In the
population with peripheral arterial disease the results
were driven mainly by non-aspirin antiplatelet drugs,
although it is often, and incorrectly, assumed that the
antiplatelet drug studied in peripheral arterial disease
was aspirin. The strength of the evidence for use of
antiplatelet agents as secondary prevention in these
groups11-14 has, however, led to the suggestion that
aspirin might be useful for primary prevention in both
diabetes and asymptomatic peripheral arterial disease.
These recommendations have been incorporated into
international society guidelines such as the joint
societies guidelines,15 and national guidelines such as
the prevention guideline on coronary artery disease
from the Scottish Intercollegiate Guidelines
Network,16 the American Heart Association,17 the
American Diabetes Association,18 and the American
CollegeofCardiology guidelines onperipheral arterial
disease.19 These guidelines are published despite the
evidence from the antithrombotic trialist meta-
analysis4 that showed no benefit from antiplatelet
therapy for primary prevention in people with
diabetes. Few data are available on aspirin for primary
prevention in patients with diabetes. The primary
prevention project trial20 compared aspirin with
placebo in patients with type 2 diabetes without
established cardiovascular disease. Aspirin failed to
achieve a significant difference in the composite
cardiovascular end point. Evidence is also conflicting
on the effects of aspirin on stroke outcomes in patients
with diabetes.21 Despite the guidelines’ recommenda-
tions, antiplatelet uptake as a primary prevention in
diabetes has been low, reflecting the uncertainty of the
value of this therapy, combined with the knowledge of
the significant side effects that can be associated with
aspirin usage.22 23
A meta-analysis24 of four randomised controlled
trials of aspirin as primary prophylaxis against cardio-
vascular events showed that although aspirin
decreased the risk of myocardial infarction it did not
reduce total mortality and might increase the risk of
stroke and of major bleeding. That meta-analysis and
another study25 concluded that on the basis of evidence
fromrandomisedcontrolled trials aspirin shouldnot be
given to all people with diabetes for primary prophy-
laxis of cardiovascular events but only to specific
subgroups.
Several haemostatic and fibrinolytic abnormalities
have been detected in patients with diabetes but the
most compelling and reproducible abnormalities have
been thoseof platelet behaviour,with enhanced release
of platelet products and platelet aggregation26; thus the
suggestion that aspirin and other antiplatelet agents
may be beneficial. Links between platelet aggregation
and the increase in oxidative stress seen in people with
diabetes27 and in thosewithperipheral arterial disease28
have been studied. Free radicals have been shown to
increase platelet aggregation, with antioxidants
decreasing aggregation.29 Defence against free radical
attack is provided in part by the body’s antioxidants.
Plasma vitamin E and ascorbic acid levels are lowered
in people with diabetes. Other scavengers have also
been reported to be decreased in people with diabetes
and in those with both diabetes and peripheral arterial
disease compared with those with peripheral arterial
disease but no diabetes.28 For these reasons interest has
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Fig 2 | Kaplan-Meier estimates in aspirin and no aspirin groups
of proportion of patients who experienced the composite end
point of death from coronary heart disease or stroke, non-fatal
myocardial infarction or stroke, or above ankle amputation for
critical limb ischaemia; and death from coronary heart disease
or stroke
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arisen in assessing antioxidant therapy in people with
diabetes.27 We determined whether aspirin and anti-
oxidant therapy, combinedor alone, aremore effective
than placebo in reducing the development of cardio-
vascular events in patients with diabetes and asympto-
matic peripheral arterial disease.
METHODS
The prevention of progression of arterial disease and
diabetes (POPADAD) trial was a multicentre, rando-
mised, double blind, placebo controlled trial. We used
a 2×2 factorial design30 to examine the efficacy and
safety of aspirin plus antioxidant compared with
aspirin alone, antioxidant alone, and placebo.
The interventions were daily aspirin 100 mg or
placebo tablet, plus antioxidant or placebo capsule.
The antioxidant capsule contained α-tocopherol
200 mg, ascorbic acid 100 mg, pyridoxine hydro-
chloride 25 mg, zinc sulphate 10 mg, nicotinamide
10mg, lecithin 9.4mg, and sodium selenite 0.8mg.We
selected this particular mix following advice from
experts in antioxidants, with approval of the Medi-
cines’ Control Agency for use as a nutritional aid in
clinical studies. The placebo tablet and capsule were
identical in appearance to the active tablet and capsule.
Participants
Participants were recruited by the Royal College of
Physicians, Edinburgh, East of Scotland Diabetic
Registry Group, which covers diabetic clinics in
hospitals in the south east of Scotland and in central
Scotland, and from clinics in the west of Scotland. The
coordinating centre was Ninewells Hospital, Dundee.
Sixteen hospital centres participated in the trial,
supported by 188 primary care groups.
Inclusion criteriawere adults of either sex, aged40or
more, with type 1 or type 2 diabetes who were
determinedashavingasymptomaticperipheral arterial
disease as detected by a lower than normal ankle
brachial pressure index (≤0.99). We selected a higher
cut-off point (0.99 v 0.9) for the trial as it is recognised
that calcification in the vessels of people with diabetes
can produce normal or high ankle brachial pressure
indexes, even in the presence of arterial disease. We
excluded peoplewith evidence of symptomatic cardio-
vascular disease; those who use aspirin or antioxidant
therapy on a regular basis; thosewith peptic ulceration,
severe dyspepsia, a bleeding disorder, or intolerance to
aspirin; those with suspected serious physical illness
(such as cancer), which might have been expected to
curtail life expectancy; those with psychiatric illness
(reported by their general practitioner); those with
congenital heart disease; and those unable to give
informed consent.
Trial procedures
Potentially eligible participants attending the diabetes
clinics during the enrolment periodwere invited to join
the trial. If they agreed they were screened for
eligibility. We scrutinised each patient’s hospital and
general practice records for evidence of symptomatic
cardiovascular disease. We excluded those not
Table 1 | Baseline characteristics. Values aremedians (interquartile ranges) unless stated
otherwise
Characteristics
Aspirin plus
antioxidant
(n=320)
Aspirin plus
placebo (n=318)
Placebo plus
antioxidant
(n=320)
Placebo plus
placebo (n=318)
Mean (SD) age
(years)
61.0 (10.0) 60.0 (10.1) 60.0 (10.3) 60.1 (9.7)
No (%) women 169 (53) 183 (58) 181 (57) 180 (57)
Time since diagnosis
of diabetes (years)
6.7 (2.9-12.9) 6.0 (2.7-13.0) 5.7 (2.4-11.7) 6.4 (2.6-11.6)
No (%) treated with
insulin
107 (33) 112 (35) 96 (30) 91 (29)
Smoking status:
No (%) current
smokers
105 (33) 99 (31) 106 (33) 87 (27)
No (%) former
smokers
113 (35) 107 (34) 111 (35) 116 (36)
No (%) never
smokers
102 (32) 112 (35) 103 (32) 115 (36)
Bodymass index (kg/
m2)
29.7 (26.2-33.3) 28.7 (25.2-33.0) 29.4 (26.1-33.5) 29.2 (25.8-33.2)
Mean (SD) systolic
blood pressure (mm
Hg)
146 (22) 143 (21) 144 (20) 147 (21)
Mean (SD) diastolic
blood pressure (mm
Hg)
79 (10) 78 (10) 79 (10) 80 (11)
Ankle brachial
pressure index
0.90 (0.82-0.95) 0.91 (0.84-0.95) 0.89 (0.81-0.94) 0.90 (0.83-0.96)
Mean (SD) HbA1c
level (%)
8.0 (1.8) 8.0 (1.7) 7.9 (1.8) 7.9 (1.7)
Total cholesterol
level (mmol/l)
5.5 (4.8-6.2) 5.6 (4.9-6.2) 5.5 (4.9-6.3) 5.5 (4.9-6.2)
Triglyceride level
(mmol/l)
2.2 (1.5-3.2) 2.2 (1.5-3.3) 2.3 (1.4-3.4) 2.1 (1.5-3.3)
High density
lipoprotein level
(mmol/l)
1.2 (1.0-1.5) 1.3 (1.0-1.5) 1.2 (1.0-1.5) 1.2 (1.0-1.5)
Low density
lipoprotein level
(mmol/l)
3.1 (2.5-3.7) 3.1 (2.5-3.7) 3.2 (2.6-3.9) 3.1 (2.6-3.7)
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Fig 3 | Kaplan-Meier estimates for aspirin andnoaspirin groups
of proportion of patients who died from any cause, compared
with proportion expected based on age and sex specific
population rates for Scotland, 2002
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currently free from symptoms of vascular disease at the
timeof this screening visit.Ankle brachial pressurewas
measured in asymptomatic patients using a standar-
dised technique.31 Training was provided to nurses
without experienceofmeasuring this pressure. Patients
with an ankle brachial pressure index of less than 1.00
were eligible for inclusion.
After providing written informed consent, patients
were randomly assigned to one of four treatment
groups: aspirin plus antioxidant, aspirin plus placebo,
antioxidant plus placebo, or double placebo. The
allocation sequence used randomisedpermutedblocks
of eight and was computer generated by the trial
statisticians. To ensure allocation concealment an
independent pharmacist packaged the drugs into
numbered containers. Recruiting nurses dispensed
the trial drugs on the day of randomisation, under the
authority of the consultant or primary care doctor.
Participants also received standard therapy as appro-
priate (for example, statins, βblockers) at the discretion
of the investigator and other responsible clinicians.We
emphasised to the investigators the use of appropriate
background cardiovascular risk reduction therapy
according to current international guidelines. The
participants, research nurses, and staff involved in
providing care were blinded to group assignment.
Follow-up evaluations were done every six months.
At these visits we recorded outcome events, adverse
events, and interventions. The results of electrocardio-
graphywere recorded at the baseline visit and annually
thereafter. The electrocardiograms were reviewed
manually for evidence of silent myocardial infarction
on the basis of criteria from theMinnesota code.When
relevant, a copy of data from hospital admissions was
obtained for use by the committee deciding on the
presence or absence of a specific end point using
predefined criteria. For example, any electrocardio-
gramsobtained fromahospital admission in the case of
a suspected myocardial infarction were also coded
using the criteria of the Minnesota code so that the
appearances of the electrocardiograms were consid-
ered in a uniform manner along with clinical and
biochemical data in reaching a decision. All primary
and secondary end points were adjudicated on a
blinded basis by the committee.
Outcome measures
We used two hierarchical composite primary end
points: death from coronary heart disease or stroke,
Table 2 | Numbers (percentages)ofpatientswithdiabeteswhoexperiencedprimaryendpoints, secondaryendpoints,andspecific
adverse events
Variable
Aspirin plus
antioxidant
(n=320)
Aspirin plus placebo
(n=318)
Placebo plus
antioxidant
(n=320)
Placebo plus
placebo (n=318)
P value
(interaction*)
Primary end points:
Composite end point† 58 (18) 58 (18) 59 (18) 57 (18) 0.92
Death from coronary heart disease
or stroke
23 (7) 20 (6) 19 (6) 16 (5) 0.90
Secondary end points:
Death (any cause) 56 (18) 38 (12) 59 (18) 42 (13) 0.93
Death from coronary heart disease 15 (5) 20 (6) 15 (5) 11 (4) 0.24
Stroke death 8 (3) 0 (0) 4 (1) 5 (2) 0.004
Non-fatal myocardial infarction 21 (7) 34 (11) 28 (9) 28 (9) 0.20
Non-fatal stroke 18 (6) 11 (4) 18 (6) 23 (7) 0.14
Above ankle amputation for critical
limb ischaemia
6 (2) 5 (2) 4 (1) 5 (2) 0.69
Transient ischaemic attack 3 (1) 11 (4) 8 (3) 12 (4) 0.25
Coronary artery bypass surgery 4 (1) 6 (2) 8 (3) 8 (3) 0.61
Coronary artery angioplasty 3 (1) 4 (1) 4 (1) 4 (1) 0.78
Development of angina 31 (10) 39 (12) 38 (12) 40 (13) 0.59
Peripheral arterial bypass surgery 3 (1) 4 (1) 1 (0.3) 4 (1) 0.44
Peripheral arterial angioplasty 6 (2) 5 (2) 6 (2) 7 (2) 0.71
Development of critical limb
ischaemia
13 (4) 8 (3) 9 (3) 10 (3) 0.37
Development of claudication 39 (12) 58 (18) 58 (18) 49 (15) 0.032
Adverse events:
Malignancy 29 (9) 24 (8) 36 (11) 32 (10) 0.85
Gastrointestinal bleeding 15 (5) 13 (4) 13 (4) 18 (6) 0.36
Gastrointestinal symptoms
including dyspepsia
33 (10) 40 (13) 36 (11) 58 (18) 0.31
Arrhythmia 28 (9) 27 (9) 22 (7) 25 (8) 0.67
Allergy, including skin rash 34 (11) 38 (12) 34 (11) 30 (9) 0.47
*Test for interaction between aspirin and antioxidant.
†Death from coronary heart disease or stroke, non-fatal myocardial infarction or stroke, or above ankle amputation for critical limb ischaemia.
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non-fatal myocardial infarction or stroke, or above
ankle amputation for critical limb ischaemia; anddeath
from coronary heart disease or stroke. Definitions for
these events were according to the World Health
Organization criteria for the diagnosis of coronary
events and strokes (fatal and non-fatal).
The main secondary end points were all cause
mortality, non-fatal myocardial infarction, and occur-
rence of other vascular events, including stroke,
transient ischaemic attack, coronary or peripheral
arterial bypass surgery, coronary or peripheral arterial
angioplasty, development of angina, claudication, or
critical limb ischaemia.
Power calculations
The event rate for similar end points in patients with
asymptomatic peripheral arterial disease in the Edin-
burgh artery study32 was 4%per annum.The event rate
in the literature at the time of the start of the trial for
patients with diabetes was between twofold and
threefold that of the population without diabetes.1-3
We originally planned to recruit 1600 participants and
follow-up each for four years. If only one treatmentwas
effective thiswould provide 90%power to detect a 25%
relative reduction in a four year event rate of 28% (8%
per annum) as significant at the 5% level. This equates
to 392 events occurring during the trial. With this
sample size but both treatments equally effective, so
slightly lower overall event rates, 343 events would be
expected in the four years of follow-up. This would still
provide greater than 80% power to detect for each
treatment the same relative reduction in event rate as
significant.
A slower than expected recruitment rate and lower
event rates led to ongoing consideration of recruitment
and termination dates by the data monitoring and
ethics committee, trial steering committee, and funding
body. Eventually 1276 patients were recruited and the
final power calculations, undertaken in 2003, projected
that if follow-up continued until June 2006 then 256
eventswouldbeexpected tooccurduring the trial.This
would give 73% power to detect a 25% relative
reduction in event rate and 89% power to detect a
30% reduction in event rate if only one treatment was
effective.
Statistical analysis
The statistical analysis followed the plan determined at
the start of the trial. The primary and secondary end
pointsweremeasuresof survival.Accordingly,weuseda
Table 3 | Comparison between aspirin and no aspirin groups in number (percentage) of patientswith diabeteswho experienced
primary end points, secondary end points, and specific adverse events
Variables Aspirin (n=638) No aspirin (n=638) Effect estimate* (95% CI) P value
Primary end points:
Composite end point† 116 (18.2) 117 (18.3) 0.98 (0.76 to 1.26) 0.86
Death from coronary heart disease or
stroke
43 (6.7) 35 (5.5) 1.23 (0.79 to 1.93) 0.36
Secondary end points:
Death (any cause) 94 (14.7) 101 (15.8) 0.93 (0.71 to 1.24) 0.63
Coronary heart disease death 35 (5.5) 26 (4.1) 1.35 (0.81 to 2.25) 0.24
Stroke death 8 (1.3) 9 (1.4) 0.89 (0.34 to 2.30) 0.80
Non-fatal myocardial infarction 55 (8.6) 56 (8.8) 0.98 (0.68 to 1.43) 0.93
Non-fatal stroke 29 (4.6) 41 (6.4) 0.71 (0.44 to 1.14) 0.15
Above ankle amputation for critical
limb ischaemia
11 (1.7) 9 (1.4) 1.23 (0.51 to 2.97) 0.64
Transient ischaemic attack 14 (2.2) 20 (3.1) 0.70 (0.36 to 1.39) 0.31
Coronary artery bypass surgery 10 (1.6) 16 (2.5) 0.62 (0.28 to 1.38) 0.24
Coronary artery angioplasty 7 (1.1) 8 (1.3) 0.88 (0.32 to 2.43) 0.81
Development of angina 70 (11.0) 78 (12.2) 0.90 (0.66 to 1.25) 0.54
Peripheral arterial bypass surgery 7 (1.1) 5 (0.8) 1.41 (0.45 to 4.43) 0.56
Peripheral arterial angioplasty 11 (1.7) 13 (2.0) 0.85 (0.38 to 1.89) 0.68
Development of critical limb
ischaemia
21 (3.3) 19 (3.0) 1.11 (0.60 to 2.06) 0.75
Development of claudication 97 (15.2) 107 (16.8) 0.89 (0.68 to 1.18) 0.42
Adverse events:
Malignancy 53 (8.3) 68 (10.7) 0.76 (0.52 to 1.11) 0.15
Gastrointestinal bleeding 28 (4.4) 31 (4.9) 0.90 (0.53 to 1.52) 0.69
Gastrointestinal symptoms,
including dyspepsia
73 (11.4) 94 (14.7) 0.77 (0.55 to 1.08) 0.081
Arrhythmia 55 (8.6) 47 (7.4) 1.19 (0.79 to 1.78) 0.41
Allergy including skin rash 72 (11.3) 64 (10.0) 1.14 (0.80 to 1.63) 0.47
*Hazard ratios (aspirin v no aspirin) for primary and secondary end points and odds ratios (aspirin v no aspirin) for adverse events.
†Death from coronary heart disease or stroke, non-fatal myocardial infarction or stroke, or above ankle amputation for critical limb ischaemia.
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Coxproportional hazardsmodel as the primarymethod
of analysis.Weassessed the interventionsby fitting terms
corresponding to aspirin, antioxidants, and the inter-
action between these treatments. As there was no
evidence of interaction we dropped this term, allowing
the overall effect of each intervention to be assessed.We
assessed the assumption of proportionality of hazards
and we used Kaplan-Meier plots for the survival
experience by treatment group. Specific adverse events
were assessed using logistic regression with terms
corresponding to aspirin, antioxidants, and the inter-
action between these treatments. As we found no
evidence of interaction we dropped this term, allowing
the overall effect of each intervention to be assessed. All
analyses were done on an intention to treat basis, with
two tailed tests of significance used throughout.
The trial was designed, planned, and executedby the
trial steering committee in collaboration with the UK
Medical Research Council. The trial was done in
accordance with good clinical practice regulations.33
Experienced research nurses collected the data, which
were entered and analysed by the Medical Statistics
Unit, University of Edinburgh. The progress of the
study was monitored throughout by the data monitor-
ing and ethics committee. This committee met at six
monthly or yearly intervals depending on the stage of
the trial. No formal stopping rules were used. The
principle employed was that early termination for
efficacy or futility would only occur if the evidencewas
assessed to be strong enough to influence practice.
RESULTS
Adults aged 40 or more with diabetes were screened
betweenNovember1997and July2001.A total of 1670
patients were potentially eligible and had an ankle
brachial pressure index of 0.99 or less. Of these, 1276
(76.4%) gave written informed consent and were
randomised; 320 to receive aspirin tablets plus anti-
oxidant capsules, 318 to receive aspirin tablets plus
placebo capsules, 320 to receive placebo tablets plus
antioxidant capsules, and318 to receiveplacebo tablets
plus placebo capsules. The treatment groups were
similar for baseline characteristics (table 1).
Follow-up
Figure 1 shows the flow of participants in the trial.
Overall, 1074 participants had their final follow-up in
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Fig 4 | Kaplan-Meier estimates for antioxidant and no
antioxidant groups of proportion of patients who experienced
thecompositeendpointofdeath fromcoronaryheartdiseaseor
stroke, non-fatalmyocardial infarctionor stroke,or aboveankle
amputation for critical limb ischaemia;anddeath fromcoronary
heart disease or stroke
Table 4 | Comparison between antioxidant and no antioxidant groups in number (percentage) of
patientswith diabeteswho experienced primary end points, secondary end points, and specific
adverse events
Variables Antioxidant (n=640)
No antioxidant
(n=636)
Effect estimate*
(95% CI) P value
Primary end points:
Composite end
point†
117 (18.3) 116 (18.2) 1.03 (0.79 to 1.33) 0.85
Death from coronary
heart disease or stroke
42 (6.6) 36 (5.7) 1.21 (0.78 to 1.89) 0.40
Secondary end points:
Death (any cause) 115 (18.0) 80 (12.6) 1.49 (1.12 to 1.99) 0.006
Coronary heart
disease death
30 (4.7) 31 (4.9) 1.01 (0.61 to 1.66) 0.99
Stroke death 12 (1.9) 5 (0.8) 2.49 (0.88 to 7.06) 0.087
Non-fatalmyocardial
infarction
49 (7.7) 62 (9.7) 0.81 (0.55 to 1.17) 0.26
Non-fatal stroke 36 (5.6) 34 (5.4) 1.08 (0.68 to 1.73) 0.74
Above ankle
amputation for critical
limb ischaemia
10 (1.6) 10 (1.6) 1.04 (0.43 to 2.50) 0.93
Transient ischaemic
attack
11 (1.7) 23 (3.6) 0.49 (0.24 to 1.00) 0.050
Coronary artery
bypass surgery
12 (1.9) 14 (2.2) 0.89 (0.41 to 1.91) 0.76
Coronary artery
angioplasty
7 (1.1) 8 (1.3) 0.89 (0.32 to 2.46) 0.82
Development of
angina
69 (10.8) 79 (12.4) 0.89 (0.65 to 1.23) 0.49
Peripheral arterial
bypass surgery
4 (0.6) 8 (1.3) 0.52 (0.16 to 1.72) 0.28
Peripheral arterial
angioplasty
12 (1.9) 12 (1.9) 1.05 (0.47 to 2.33) 0.92
Development of
critical limb ischaemia
22 (3.4) 18 (2.8) 1.28 (0.68 to 2.38) 0.45
Development of
claudication
97 (15.2) 107 (16.8) 0.94 (0.72 to 1.24) 0.67
Adverse events:
Malignancy 65 (10.2) 56 (8.8) 1.17 (0.80 to 1.71) 0.41
Gastrointestinal
bleeding
28 (4.4) 31 (4.9) 0.89 (0.53 to 1.51) 0.67
Gastrointestinal
symptoms, including
dyspepsia
69 (10.8) 98 (15.4) 0.66 (0.48 to 0.92) 0.015
Arrhythmia 50 (7.8) 52 (8.2) 0.95 (0.64 to 1.43) 0.81
Allergy including
skin rash
68 (10.6) 68 (10.7) 0.99 (0.70 to 1.42) 0.97
*Hazard ratios (antioxidant v no antioxidant) for primary and secondary end points and odds ratios (antioxidant
v no antioxidant) for adverse events.
†Death from coronary heart disease or stroke, non-fatal myocardial infarction or stroke, or above ankle
amputation for critical limb ischaemia.
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2006, six had moved away and were lost to follow-up,
one withdrew consent after four years, and 195 died
during the trial. The median length of follow-up for
randomised participants was 6.7 years and for those
with a final follow-up in 2006 follow-up ranged from
4.5 to 8.6 years. A total of 8127 patient years of follow-
up were completed.
End points
Overall, 233 participants experienced the composite
primary endpoint of death fromcoronaryheart disease
or stroke, non-fatal myocardial infarction or stroke, or
above ankle amputation for critical limb ischaemia, an
overall event rate of 2.9 per 100 patient years. Seventy
eight participants died from coronary heart disease or
stroke, an event rate of 1.0 per 100 patient years.
Table 2 shows the proportion of participants by
treatment group who experienced each end point or
specific adverse event.
The interaction between the aspirin and antioxidant
treatments was not statistically significant either for the
composite primary end point (P=0.88) or for death
from coronary heart disease or stroke (P=0.95). In
addition, the interaction between the two treatments
was statistically significant for only two of the
secondary end points—death from stroke (P=0.004)
and the development of claudication (P=0.032). No
evidence was found of an interaction for the specific
adverse events. Because there was no evidence of an
interactionbetweenaspirin andantioxidant, patients in
the two groups randomised to receive aspirin were
compared with those in the two groups randomised to
receive placebo tablets (no aspirin), and patients in the
two groups randomised to receive antioxidant were
compared with those in the two groups randomised to
receive placebo capsules (no antioxidant).
Aspirin versus no aspirin
Table 3 shows the proportion of participants with each
of the primary and secondary end points in the aspirin
and no aspirin groups. Figure 2 shows the cumulative
percentages of patients over time who experienced
each of the primary end points. The differences
between these two groups were not statistically
significant for either of the primary end points.
Figure 3 presents the cumulative percentages of
patients over timewho died fromany cause, alongwith
the percentage expected for all patients based on age
and sex specific mortality rates for Scotland, 2002
(General Registrar Office, Scotland). No statistically
significant differences were found between the aspirin
and no aspirin groups for any of the secondary end
points. Specific adverse event rates were not statisti-
cally significantly different between the aspirin and no
aspirin groups (table 3).
Antioxidant versus no antioxidant
Table 4 presents the proportion of patients who
experienced each of the primary and secondary end
points in the antioxidant and no antioxidant groups.
Figure 4 shows the cumulative percentages of patients
over time who experienced each of the primary end
points. No statistically significant differences were
found between these two groups for either of the
primary end points.
Figure 5 shows the cumulative percentages of
patients over time who died from any cause, along
with the percentage expected for all patients based on
age and sex specific population rates for Scotland. The
increase in numbers of deaths from any cause in the
antioxidant group compared with the no antioxidant
group was statistically significant (P=0.006). This
difference in all cause mortality seems to be partly
due to a relative deficiency of deaths in the no
antioxidant group compared with an age and sex
matched Scottish population and partly due to a
relative excess of deaths in the antioxidant group. No
statistically significant differences were found between
the antioxidant and no antioxidant groups for any of
the other secondary end points.
Specific adverse event rates were not statistically
significantly different in the antioxidant and no anti-
oxidant groups, except for gastrointestinal symptoms
Table 5 | Cause of death in patientswith diabetes according to treatment group
Causes of death
Aspirin plus
antioxidant (n=56)
Aspirin plus
placebo (n=38)
Placebo plus
antioxidant (n=59)
Placebo plus
placebo (n=42)
Myocardial infarction 11 10 8 5
Other coronary heart
disease
4 10 7 6
Stroke:
Ischaemic 3 0 3 2
Haemorrhagic 2 0 1 2
Unknown cause 3 0 0 1
Other cardiac 5 0 4 1
Other vascular 3 1 2 2
Cancer 16 9 18 13
Trauma 0 0 2 0
Other 9 8 14 10
Time (years)
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Fig 5 | Kaplan-Meier estimates for antioxidant and no
antioxidant groups of proportion of patients who died from any
cause, compared with proportion expected based on age and
sex specific population rates for Scotland, 2002
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includingdyspepsia (P=0.015),whichwere reportedby
more patients in the no antioxidant groups.
Cause of death
The end points committee classified the deaths as
coronary heart disease, stroke, other cardiac, other
vascular, cancer, trauma, or other. The deaths from
coronary heart disease were further classified as being
due to myocardial infarction or other coronary heart
disease, whereas the deaths from stroke were classified
as ischaemic, haemorrhagic, or of unknown cause.
More deaths occurred in the antioxidant groups than
no antioxidant groups for all the categories except
other coronary heart disease (table 5).
Subgroup analyses
Although subgroup analyses were planned, the trial
steering committee asked that analyses of the primary
end points compared aspirin and no aspirin groups by
subgroups of age, sex, or ankle brachial pressure index.
This was because of concern that particular patients
with an ankle brachial pressure index of less than 0.90,
which defines peripheral arterial disease, may have
been at higher risk and so might have shown some
benefit in this subgroup. The difference in treatment
effect between the subgroups was not statistically
significant for any of the three characteristics (table 6).
Trial drugs
The cumulative percentage of patients who stopped
taking the tablets (aspirin or placebo) before they
experienced the composite primary end point, died,
moved abroad, withdrew consent, or completed the
study was 14% by the end of one year. Thereafter
withdrawal from trial therapy was fairly constant,
leading to a cumulative rate of 50% after five years.
DISCUSSION
We evaluated the effect of aspirin or antioxidant on
cardiovascular events andmortality in a large cohort of
people with diabetes mellitus with asymptomatic
peripheral arterial disease. These two clinical criteria
were selected for study as guidelines15-18 were being
published, without evidential support, recommending
aspirin use as primary prevention of cardiovascular
disease in patients with diabetes mellitus and with
asymptomatic peripheral arterial disease.We foundno
evidence of benefit from either aspirin or antioxidant
treatment on the composite hierarchical primary end
points of cardiovascular events and cardiovascular
mortality. The lower 95% confidence limits for these
primary end points, however, only just excluded a 25%
benefit for aspirin and a 23% benefit for antioxidant,
whereas the upper 95% confidence limits only just
excluded a 27% increase in cardiovascular events for
aspirin and a 34% increase for antioxidant. Clinically
important benefits are unlikely from the results of this
study, although it is possible that small effects may be
shown with larger trials continued for a longer time.
Wepreferred the 2×2 factorial design to two separate
trials because it had major advantages.30 Firstly, it
greatly reduced the number of patients needed to
achieve the specified statistical power on the assump-
tion that aspirin and antioxidant did not interact.
Secondly, using such a designprovided an opportunity
for testing the interaction between the two
Table 6 | Comparison of aspirin andno aspirin groups in subgroups of specified baseline characteristics for primary end points
Primary end point
Aspirin No aspirin
Hazard ratio (95% CI) P value*No of patients
No (%) with
event No of patients
No (%) with
event
Composite end point†
Age (years):
<60 297 38 (12.8) 315 36 (11.4) 1.11 (0.70 to 1.75)
0.44
≥60 341 78 (22.9) 323 81 (25.1) 0.89 (0.65 to 1.21)
Women 352 48 (13.6) 361 55 (15.2) 0.89 (0.60 to 1.31)
0.54
Men 286 68 (23.8) 277 62 (22.4) 1.04 (0.74 to 1.47)
Ankle brachial
pressure index:
≤0.90 314 59 (18.8) 332 75 (22.6) 0.81 (0.58 to 1.14)
0.089
0.91-0.99 324 57 (17.6) 306 42 (13.7) 1.28 (0.86 to 1.91)
Death from coronary heart disease or stroke
Age (years):
<60 297 10 (3.4) 315 10 (3.2) 1.07 (0.44 to 2.56)
0.77
≥60 341 33 (9.7) 323 25 (7.7) 1.24 (0.74 to 2.09)
Women 352 17 (4.8) 361 16 (4.4) 1.09 (0.55 to 2.16)
0.68
Men 286 26 (9.1) 277 19 (6.9) 1.33 (0.73 to 2.40)
Ankle brachial
pressure index:
≤0.90 314 22 (7.0) 332 24 (7.2) 0.96 (0.54 to 1.71)
0.17
0.91-0.99 324 21 (6.5) 306 11 (3.6) 1.84 (0.89 to 3.82)
*Test for heterogeneity of treatment effect in subgroups.
†Death from coronary heart disease or stroke, non-fatal myocardial infarction or stroke, or above ankle amputation for critical limb ischaemia.
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interventions, although the power to detect an inter-
action was low. This design yields double the informa-
tion of single factorial designs.
In examining why aspirinmay have been ineffective
the question was asked as to whether these patients
were at sufficient risk, in terms of peripheral arterial
disease, as the cut-off point of an ankle brachial
pressure index of 0.99 or less is higher than that used
to define peripheral arterial disease in the population
(<0.9).31 A subgroup analysis did not, however, find
evidence of a difference in effect of aspirin between
those with an index of 0.91-0.99 and those below this
level. Furthermore, one of the current major inter-
ventions in the specialty of diabetes mellitus is statin
therapy. Calculations by two of the centres (DM and
CK) in over 10 000 people with diabetes showed a
mean total cholesterol level of 6.0 mmol/l in 1996
decreasing to 4.3 mmol/l in 2007. As aspirin was the
first drug to have an evidence base for secondary
prevention of cardiovascular disease it is always given
to patients in subsequent trials and it might be asked if
aspirin does indeed provide additional benefit when
statins are used to good effect.
The importance of the neutral effect of aspirin on
cardiovascular events is that this drug is not without
side effects.23 Aspirin is themost commonly prescribed
drug in Scotland, with about 544 438 person years
exposure per year in 2002. The number of prescrip-
tions is increasing. The overwhelmingmajority of this,
in the region of Tayside at least, is prescription based,
with only about 7% being from over the counter use.
Aspirin is one of the top 10 causes of adverse drug
events reported to the Commission on Human
Medicines. Gastrointestinal bleeding is associated
with general use of non-steroidal anti-inflammatory
drugs inover80%of reportedcases, and87%of thatuse
is associated with aspirin, either alone or with other
non-steroidal anti-inflammatory drugs.34 The risk of a
bleeding event increases with age and also continuous
exposure.23 Although the calculated risk of major
bleeding is relatively small,35 the number of people
taking aspirin is relatively large and therefore in
population terms aspirin induced bleeding is a major
problem. In ameta-analysis thenumberneeded to treat
to cause an adverse event has been calculated as 248,36
and this is relevant to the large and increasing
population with diabetes.
Of concern was the fact that there was a tendency to
harm in the antioxidant group. It should be noted that
the increase in number of deaths in the antioxidant
groups seems to partly reflect better survival than
expected of the groups who did not receive anti-
oxidants, rather than just an obvious negative effect of
the antioxidants. Thus this may at least in part be a
difference achieved by chance. This agrees with
recently published work,37 and these data should be
added to future systematic reviews and meta-analyses.
Anecdotally, many people with diabetes supplement
with antioxidants after major publicity in the lay press
of a deficiency in antioxidants in such people. We
found no evidence for this perceived benefit from our
study.
We found no evidence to support the use of either
aspirin or antioxidants in the primary prevention of
cardiovascular events and mortality in people with
diabetes. Aspirin should, however, still be given for
secondary prevention of cardiovascular disease in
people with diabetes mellitus, when the evidence
base is convincing, and the results of this study must
not detract from this important standard of care.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Aspirin is effective in the secondary prevention of
cardiovascular events in patients with symptomatic
peripheral arterial disease and with or without diabetes
Aspirin is responsible for significant gastrointestinal
morbidity
No large intervention trial has shownany reductionof events
with antioxidant intervention
WHAT THIS STUDY ADDS
Aspirin was not effective in the primary prevention of
cardiovascular events in patients with asymptomatic
peripheral arterial disease and diabetes
Antioxidants showed no benefit on cardiovascular events in
this population
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